BioCentury
ARTICLE | Company News

Incyte, Pharmasset deal

August 29, 2005 7:00 AM UTC

Pharmasset received a $1.5 million milestone payment from INCY under a 2003 deal in which INCY received exclusive development and marketing rights to Pharmasset's Reverset reverse transcriptase inhibi...